The Investor
30 Sep 2026, 19:15
Moderna Stock Falls 6.3% as Citi Downgrades Shares to Sell
Moderna shares fell 6.3% after Citigroup downgraded the biotechnology company to Sell from Neutral while raising its price target to $80 from $60.
Despite the higher target, the Sell rating signals a more cautious overall view on the stock relative to its current price of about $190.64.
More broadly, Moderna remains highly sensitive to expectations around its post-COVID revenue base, the commercial performance of newer vaccines and the timing and probability of success across its pipeline. Elevated research and development spending, continued cash burn and uncertainty around how quickly new products can offset declining legacy vaccine revenue are probable factors behind a more conservative stance.
The sharp decline suggests investors focused primarily on the downgrade and the large gap between the analyst’s $80 target and Moderna’s current share price.
Moderna shares fell 6.3% after Citigroup downgraded the biotechnology company to Sell from Neutral while raising its price target to $80 from $60.
Despite the higher target, the Sell rating signals a more cautious overall view on the stock relative to its current price of about $190.64.
More broadly, Moderna remains highly sensitive to expectations around its post-COVID revenue base, the commercial performance of newer vaccines and the timing and probability of success across its pipeline. Elevated research and development spending, continued cash burn and uncertainty around how quickly new products can offset declining legacy vaccine revenue are probable factors behind a more conservative stance.
The sharp decline suggests investors focused primarily on the downgrade and the large gap between the analyst’s $80 target and Moderna’s current share price.
